Baird: Your response gets to the meat of the matter. The point of the party here is to comparison shop biotechs. Clearly, the only possible way to accomplish this is to compare the actual science done by individual companies. I think its absolutely essential to keep the science first. KEEP THE SCIENCE FIRST. It is astonishing the number of posts on biotech threads that have to do with financing, investor relations announcements, hired consultants, etc. And non-science folks need not be dazzled by the language - keep in mind, the lingo was coined to promote brevity and avoid ambiguity. Unfortunately it is often used to promote the reverse, many times by biotech firms; Ph.D.s on SI are well aware of this advantage and many exercise their prerogative. This was attempted last night on this thread. The behavior was especially contemptuous in this case because of the quantity of posts and the clear knowledge of the exposure this thread had achieved. If it happens again, I will request that Jill eliminate this forum.
My request is simple: if you were already foolish enough to earn a Ph.D., try to regain your civility: share your knowledge and expertise in a concise manner so that a large, mostly non-science audience can understand.
Which brings me to Sibia. The tone of my post may have been too aggressive - again, my knowledge of Sibia is nil and their approach to neurological disorders may be novel. I clearly did not abide by my own rules in bombarding you with questions about Parkinson's disease and I apologize. I do believe its essential that you focus your investment energies on learning about the nicotinic acetylcholine receptor and its potential as a global treatment for brain disorders. This may sound daunting but think of it this way: you've probably read though a number of SEC statements to learn about companies: there is no language more esoteric and convoluted that the financial BS. Try going to the PubMed site, look up your company and/or your drug and read the abstract(s). The last sentence or two usually is in a language which most closely resembles English. Then come back here. I do NOT think its a good idea to gather info on the threads of individual companies. Once again, as was shown last night, the likelihood of receiving reliably objective information is minimal.
And Baird, your candor is refreshing. Stay with us.
I gotta go.
Best wishes,
Peter |
